At present, the biopharmaceutical industry is entering a golden period of development, with continuous breakthroughs in cutting-edge technologies and innovative projects with core barriers and clear commercialization paths, becoming a key direction for capital and industrial layout.

This article continues to select 6 high-quality innovative projects, covering multiple fields such as exosome delivery, fullerene applications, RNA drugs, IVD diagnosis, stem cell technology and service implementation, all of which have mature core technology support, complete patent layout, and clear commercialization paths. Some projects have entered the implementation stage and have outstanding industrial value.

We will fully open up multiple channels for equity investment, industrial mergers and acquisitions, and authorized cooperation to investment institutions, listed companies, and industry partners, providing opportunities for cooperation for all parties.

We sincerely invite partners from all walks of life to join hands and seize opportunities for the development of innovative industries, achieve mutual empowerment of technology and capital, and embark on a new journey in the industry together

---

The following is a detailed introduction to the 6 high-quality innovative assets of this issue:

1、 Extracellular vesicles | RNA delivery and clinical extracellular vesicle drugs

This project focuses on the global high barrier innovation track of central nervous system (CNS) drug delivery, constructing a dual core asset of “natural exosome drug pipeline+central RNA delivery platform”. The front-end layout includes major unmet clinical indications such as severe pulmonary inflammation, stroke, Alzheimer’s disease, Parkinson’s disease, and heart failure. Some pipelines have accumulated human case and IIT data, with clear clinical translation and registration application basis; The backend focuses on engineered biological vesicles, overcoming key bottlenecks such as low efficiency of RNA drugs crossing the blood-brain barrier, insufficient distribution in the brain, and poor safety of long-term administration. It is compatible with siRNA, mRNA, circRNA, and gene editing payloads, achieving multi RNA co loading and long fragment loading. The low efficiency of functional gene knockout in the brain reaches 40% -60%, and the nasal administration pathway is laid out, which is more suitable for long-term treatment of chronic CNS diseases.

From the perspective of investment value, the project forms a dual growth logic of short-term clinical monetization and medium – to long-term platform barriers: natural extracellular vesicle drugs can quickly promote clinical and registration, contributing proximal value; The central RNA delivery platform has replicable and scalable underlying technical capabilities, and has both self-developed iteration and external authorization cooperation space. At present, the company has conducted CMC, process amplification, and authorization cooperation negotiations with overseas enterprises, and the industrialization and internationalization path is clear. The proposed Series A financing of 50-100 million yuan will mainly be used for clinical promotion, GMP production capacity construction, and RNA delivery platform upgrade. It is a high-quality pharmaceutical innovation asset with both deterministic conversion value and long-term technical barriers.

---

2、 Innovative Medicine | Fullerene Multi Scene Conversion Platform

This project takes fullerene as the core underlying technology platform, and constructs a full chain technology system from high-purity raw material preparation, purification and separation, quality control, formulation development, pharmacological research to application transformation. Unlike traditional single tube type R&D enterprises, its core value lies in the ability to independently control key materials, innovate drug research and development capabilities, and multi scenario industrialization extension capabilities. It can achieve collaborative layout and value resonance in the fields of medicine, new materials, consumer health, etc., with deep technical barriers and outstanding risk resistance capabilities.

From the perspective of investment highlights, the project relies on the unique antioxidant, anti-inflammatory, and multi-target regulatory mechanisms of fullerene to lay out multiple high-value innovative drug pipelines in the pharmaceutical field, such as tumor support therapy, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases. It has the advantages of strong mechanism commonality and high platform reusability. The core assets have entered the clinical application and preparation stage, and the pace of research and development promotion is clear; At the same time, it has entered the leading perovskite industry chain and entered the evaluation and application system in the industry. The consumer goods and cosmetics fields also have market acceptance capabilities, forming a dual wheel drive model of long-term value of innovative drugs and short-term industrialization of new materials, effectively balancing research and development investment and cash flow support. It is a high-quality target that combines technical barriers, clinical certainty, and diversified commercialization paths.

---

3、 RNA drugs | siRNA pipeline and extrahepatic delivery platform

This project focuses on innovative development of RNA drugs and has established a three-dimensional layout of “clinical core assets+extrahepatic delivery technology platform+diversified pipeline reserve”. The core product is GalNAc siRNA targeting TTR, which is used to treat ATTR-CM and ATTR-PN. Currently, it has carried out Phase I clinical trials in China and obtained FDA orphan drug qualification. The first human data confirms its excellent PK/PD characteristics and safety. It is planned to adopt a subcutaneous injection regimen every 6 months, with outstanding treatment compliance and commercial value. The core patent has passed PCT and China layout, and the protection period can cover until 2044-2045. The product has significant lifecycle advantages.

From the perspective of investment value, the project relies on an independently constructed extrahepatic delivery platform with RNA sequence design, chemical modification, and AI optimization capabilities, making breakthrough progress in the fields of adipose tissue and skeletal muscle delivery. Low dose administration can achieve over 70% target gene knockdown and demonstrate clear weight loss efficacy. The skeletal muscle delivery gene knockdown rate is about 75%, providing a replicable technical foundation for metabolic, cardiovascular, and other disease fields; At the same time, the company continues to expand its pipeline around cardiovascular, metabolic, and renal diseases, with multiple projects in the discovery to pre IND stage. It plans to submit 5 IND and promote 2 key projects into IND enabling research before 2027. The team covers the entire chain of RNA research and development, delivery, CMC, and clinical development, forming a multiple value drive of “clinical asset monetization+platform technology empowerment+pipeline continuous iteration”, with dual growth space for independent commercialization and external cooperation authorization.

---

4、 IVD | breast cancer Precision Layering Platform

This project focuses on the rigid clinical demand of accurate decision-making for post-operative adjuvant treatment of breast cancer, and has built a high-quality IVD asset system of “overseas mature verification+Chinese localization+rapid expansion of multiple cancer types”. The core product is a label free detection system based on spectral imaging, digital pathology, and AI algorithms, which can efficiently assess the risk of recurrence, guide chemotherapy decisions, and stratify treatment; This product has completed independent clinical validation in the UK and has been compared head to head with mainstream genetic testing products. Its 10-year recurrence risk prediction performance is superior to the control product, and it has significant advantages: sample processing only requires reports within 2 and 24 hours, and the testing cost is only one-third of traditional genetic testing. It has strong competitiveness in clinical timeliness, accessibility, and health economics.

From the perspective of investment value, the project has achieved breakthroughs in overseas commercialization, been approved for payment in the UK, and has formed clinical applications and reimbursement cases in multiple countries in India, Southeast Asia, and Latin America, validating the business model; The domestic end relies on reference laboratories, cloud based AI, and pilot zone policies to quickly implement, prioritizing the coverage of core pathology and detection networks in Jiangsu, Zhejiang, and Shanghai. It is easy to embed into routine pathology processes and deeply collaborate with hospital cost control and commercial insurance. At the same time, the product can rapidly expand from breast cancer to lung cancer, colorectal cancer, esophageal cancer, nasopharyngeal cancer, kidney cancer and other high incidence cancers, with platform expansion potential. Overall, this project has clear clinical value, a clear commercialization path, prominent cost and efficiency advantages, and broad expansion space, making it a scarce IVD investment target with both short-term landing capability and long-term growth value.

---

5、 Regenerative Medicine | Autologous Stem Cell Small Molecule Reversal Technology Platform

This project focuses on the full chain technology and transformation application of autologous stem cells derived from blood, and has built a complete innovative system from efficient preparation, safe storage to clinical transformation. The core technology uses peripheral blood mononuclear cells as raw materials and achieves safe and compliant stem cell preparation through a non viral, non gene edited small molecule targeted induction system; Only 80-150ml of venous blood is needed to obtain billion grade primary autologous stem cells. Hematopoietic stem cells can be prepared in 6 days, and more than ten types of stem cells such as hematopoietic, mesenchymal, neural, retinal, pancreatic, liver, heart, and kidney can be obtained in bulk. It has industry-leading advantages in preparation efficiency, cell types, and scalability.

The most prominent investment highlights of this project are autologous sources, non-invasive materials, no immune rejection, no matching requirements, and no risk of cross infection. At the same time, it avoids regulatory and safety risks of virus vectors and gene editing, and has a clearer clinical translation path with significant ethical and approval advantages. The project has a profound technical accumulation, dating back to 1998, with complete intellectual property rights, and has established an innovation consortium with the Shenzhen Advanced Institute of the Chinese Academy of Sciences. Key cell indicators have been verified by CNAS. At the clinical end, we focus on diabetes, knee arthritis, chronic kidney disease and other high demand indications through the breakthrough of domestic Grade III A hospitals IIT/IND; Overseas, relying on Hong Kong’s Hetao layout for production and medical care systems, and synchronously building a strategic bank of adult autologous stem cells, forming a diversified income model of cell preparation+storage services+clinical applications+health management. This round of Pre-A/A financing of 50-200 million yuan will be used for clinical cooperation, capacity building, and market expansion. It is a high-quality stem cell track target that combines underlying technical barriers, clinical translation certainty, and long-term business model scalability.

---

6、 Medical Services | Internet Medical and Precision Health Management Platform Driven by Doctor Group

The project has built an online and offline integrated precision medical service platform, built a closed-loop service system of “doctor group operation – Internet diagnosis and treatment – cloud medicine service – offline specialized outpatient service – accurate detection – full cycle health management”, and officially obtained the qualification of Internet hospital in October 2024, with the core ability to carry out online diagnosis and treatment services in compliance. The platform has gathered over 1000 online physicians, including over 500 chief physician level experts, forming a strong barrier expert resource network. With the support of multiple operational systems in Beijing, Hangzhou, Shanghai, and Seoul, it has achieved the coordinated implementation of doctor operations, digital platforms, patient services, and international medical resources.

The project focuses on endocrine chronic disease, tumor management and high-end accurate detection track. It has established cooperation with Shanghai New Hongqiao International Medical Center, Seoul Hospital of Lihua Women’s University in Korea and other institutions, and has laid out special services such as gastroscopy, cell subpopulation, tumor vaccine, intestinal flora, etc., forming a standardized and replicable chronic disease management scheme, especially in the field of type II diabetes, which has achieved full process closed-loop services. What is more valuable for investment is that the project has completed the construction of overseas capital structure. The controlling entity entered the US OTC market through RTO in 2021 and transferred to the OTCQB sector in 2022. It has a mature capital operation foundation, combined with compliance licenses, high-quality doctor resources, international cooperation networks, and diversified service monetization capabilities, forming multiple advantages of license barriers, resource barriers, channel barriers, and capital channels. It is a high-quality target in the medical service field that combines landing, growth, and capital extension.

---

The six high-quality innovative assets gathered this time are all centered on cutting-edge technology, guided by clinical needs, and aimed at market growth. They cover exosome delivery, fullerene applications, RNA drugs, IVD diagnosis, regenerative medicine, and medical services, and can fully adapt to capital investment, industry mergers and acquisitions, cross-border BD, and commercial cooperation.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.